المؤلفون: Wang, X, Wang, SS, Huang, H, Cai, L, Zhao, L, Peng, RJ, Lin, Y, Tang, J, Zeng, J, Zhang, LH, Ke, YL, Wang, XM, Liu, XM, Chen, QJ, Zhang, AQ, Xu, F, Bi, XW, Huang, JJ, Li, JB, Pang, DM, Xue, C, Shi, YX, He, ZY, Lin, HX, An, X, Xia, W, Cao, Y, Guo, Y, Su, YH, Hua, X, Wang, XY, Hong, RX, Jiang, KK, Song, CG, Huang, ZZ, Shi, W, Zhong, YY, Yuan, ZY

المصدر: JAMA. 325(1):50-58

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:145328027

المؤلفون: Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ

المصدر: Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 223-231 (2024)

مصطلحات موضوعية: adjuvant chemotherapy, capecitabine, sysucc-001, triple-negative breast cancer, tnbc, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.dovepress.com/does-the-dose-of-standard-adjuvant-chemotherapy-affect-the-triple-nega-peer-reviewed-fulltext-article-BCTT; https://doaj.org/toc/1179-1314

URL الوصول: https://doaj.org/article/49c93cae53b24fb1863b44ec490bf852

المؤلفون: Hua X; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Bi XW; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Zhao JL; Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China., Shi YX; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Lin Y; Thyroid and Breast Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China., Wu ZY; Department of Oncology Surgery, Diagnosis and Treatment Center of Breast Diseases, Affiliated Shantou Hospital, Sun Yat-sen University, Shantou, China., Zhang YQ; Department of Vascular Surgery, Affiliated Hospital of Guangdong Medical College, Zhanjiang, China., Zhang LH; Department of Breast Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Zhang AQ; Department of Breast Oncology, Maternal and Child Health Care Hospital of Guangdong Province, Guangzhou, China., Huang H; Department of Breast Oncology, Lianjiang Pepole's Hospital, Lianjiang, China., Liu XM; Department of Breast Oncology, Haikou People's Hospital, Haikou, China., Xu F; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Guo Y; Department of Good Clinical Practice, the State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Xia W; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Hong RX; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Jiang KK; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Xue C; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., An X; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Zhong YY; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Wang SS; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Huang JJ; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China., Yuan ZY; Department of Medical Oncology, the State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Feb 15; Vol. 28 (4), pp. 637-645.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Aromatase Inhibitors ; Disease-Free Survival ; Female ; Humans ; Receptor, ErbB-2 ; Trastuzumab ; Treatment Outcome

المؤلفون: Xia W; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Wang SS; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Hu H; China National Health Development Research Center, Beijing 100044, China., Zhao FL; School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, The University of Newcastle, Callaghan 2308, Australia., Xu F; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Hong RX; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Jiang KK; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Yuan ZY; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Shi YX; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Zhao K; China National Health Development Research Center, Beijing 100044, China., Huang JJ; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Xue C; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Bi XW; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Lu QY; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., An X; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China., Zhang JM; Department of Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

المصدر: Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2020 Oct 23; Vol. 42 (10), pp. 861-867.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Chinese Medical Association Country of Publication: China NLM ID: 7910681 Publication Model: Print Cited Medium: Print ISSN: 0253-3766 (Print) Linking ISSN: 02533766 NLM ISO Abbreviation: Zhonghua Zhong Liu Za Zhi Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/economics, Febrile Neutropenia/*prevention & control , Granulocyte Colony-Stimulating Factor/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; China ; Cost-Benefit Analysis ; Female ; Granulocyte Colony-Stimulating Factor/economics ; Humans ; Markov Chains ; Middle Aged ; Recombinant Proteins/economics ; Recombinant Proteins/therapeutic use

المؤلفون: Wang JH; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P.R China., Zhao LF; Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, Guangzhou, P.R China., Wang HF; Shunde Hospital, Southern Medical University, Foshan, P.R China., Wen YT; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P.R China., Jiang KK; Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, P. R. China., Mao XM; Department of Urology, Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, P.R China., Zhou ZY; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P.R China., Yao KT; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P.R China., Geng QS; Guangdong General Hospital, Guangzhou, China., Guo D; Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, P.R China., Huang ZX; Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, P.R China.

المصدر: Bioinformatics (Oxford, England) [Bioinformatics] 2019 Nov 04. Date of Electronic Publication: 2019 Nov 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 9808944 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1367-4811 (Electronic) Linking ISSN: 13674803 NLM ISO Abbreviation: Bioinformatics Subsets: MEDLINE